Among 9 analysts covering Atricure Inc. (NASDAQ:ATRC), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Atricure Inc. had 35 analyst reports since July 30, 2015 according to SRatingsIntel. Piper Jaffray initiated it with “Buy” rating and $2600 target in Tuesday, May 30 report. The firm has “Buy” rating given on Tuesday, August 4 by Needham. Needham maintained it with “Buy” rating and $25.0 target in Thursday, November 2 report. Dougherty & Company maintained it with “Buy” rating and $30 target in Tuesday, July 28 report. Canaccord Genuity maintained the stock with “Buy” rating in Monday, September 4 report. The stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Outperform” rating by Northland Capital on Tuesday, March 29. The firm has “Buy” rating given on Thursday, July 27 by Stifel Nicolaus. The stock of AtriCure, Inc. (NASDAQ:ATRC) has “Buy” rating given on Monday, July 10 by Canaccord Genuity. The firm has “Buy” rating given on Tuesday, February 27 by Canaccord Genuity. The firm earned “Buy” rating on Friday, August 7 by BTIG Research. See AtriCure, Inc. (NASDAQ:ATRC) latest ratings:
27/04/2018 Broker: BTIG Research Rating: Hold
27/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $22 New Target: $23 Maintain
27/04/2018 Broker: Needham Rating: Buy New Target: $26.0000 Maintain
27/02/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain
27/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $26 Maintain
16/01/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $24.0 Maintain
The stock of New Age Beverages Corporation (NASDAQ:NBEV) hit a new 52-week low and has $1.55 target or 7.00% below today’s $1.67 share price. The 6 months bearish chart indicates high risk for the $65.48 million company. The 1-year low was reported on Jun, 14 by Barchart.com. If the $1.55 price target is reached, the company will be worth $4.58 million less. The stock decreased 1.76% or $0.03 during the last trading session, reaching $1.67. About 227,752 shares traded. New Age Beverages Corporation (NASDAQ:NBEV) has declined 71.77% since June 14, 2017 and is downtrending. It has underperformed by 84.34% the S&P500. Some Historical NBEV News: ; 17/04/2018 – NEW AGE BEVERAGES CORP NBEV.O QUARTERLY GROSS REVENUE $12.38 MLN VS $11.27 MLN; 15/05/2018 – NEW AGE BEVERAGES CORP – QTRLY GROSS REVENUES REACHED $12.8 MLN VERSUS $11.4 MLN IN THE PRIOR YEAR, AN INCREASE OF 11.6%; 23/04/2018 – DJ New Age Beverages Corp, Inst Holders, 1Q 2018 (NBEV); 13/04/2018 – NEW AGE BEVERAGES CORP – TERMINATED AT MARKET ISSUANCE SALES AGREEMENT DATED MARCH 23, BETWEEN CO & B. RILEY FBR; 02/04/2018 NEW AGE BEVERAGES CORP FILES FOR NON-TIMELY 10-K WITH U.S. SEC
More recent New Age Beverages Corporation (NASDAQ:NBEV) news were published by: Seekingalpha.com which released: “Pass On New Age Beverages” on May 22, 2018. Also Seekingalpha.com published the news titled: “New Age Beverages’ (NBEV) CEO Brent Willis on Q1 2018 Results – Earnings Call Transcript” on May 17, 2018. Digitaljournal.com‘s news article titled: “New Age Beverages Corporation Invited to Present at the Oppenheimer 18th Annual Consumer Conference on June …” with publication date: June 12, 2018 was also an interesting one.
New Age Beverages Corporation, a healthy functional beverage company, engages in the development, marketing, sales, and distribution of beverages. The company has market cap of $65.48 million. It offers ready to drink tea, kombucha, energy drinks, and functional waters under XingTea, XingEnergy, Aspen Pure, and Bucha Live Kombucha brand names. It currently has negative earnings. The firm offers its products directly, as well as through store delivery distribution systems in the United States and internationally.
Another recent and important AtriCure, Inc. (NASDAQ:ATRC) news was published by Businesswire.com which published an article titled: “AtriCure Announces 2018 Analyst and Investor Meeting” on June 12, 2018.
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $868.29 million. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.
The stock decreased 0.40% or $0.1 during the last trading session, reaching $24.78. About 10,875 shares traded. AtriCure, Inc. (NASDAQ:ATRC) has risen 14.67% since June 14, 2017 and is uptrending. It has outperformed by 2.10% the S&P500. Some Historical ATRC News: ; 14/05/2018 – T Rowe Price Associates Buys New 4.3% Position in AtriCure; 26/04/2018 – AtriCure Backs 2018 Rev $190M-$196M; 26/04/2018 – AtriCure 1Q Rev $47M; 31/05/2018 – AtriCure at Non-Deal Roadshow Hosted By Northland Today; 17/05/2018 – CEO Carrel Gifts 325 Of AtriCure Inc; 26/04/2018 – ATRICURE 1Q REV. $47.0M, EST. $45.4M; 26/04/2018 – ATRICURE 1Q LOSS/SHR 31C, EST. LOSS/SHR 27C; 02/04/2018 AtriCure Closes Below 200-Day Moving Average: Technicals; 19/04/2018 – DJ AtriCure Inc, Inst Holders, 1Q 2018 (ATRC); 26/04/2018 – AtriCure 1Q Loss/Shr 31c
Investors sentiment decreased to 0.78 in 2018 Q1. Its down 0.35, from 1.13 in 2017Q4. It dropped, as 10 investors sold AtriCure, Inc. shares while 41 reduced holdings. 14 funds opened positions while 26 raised stakes. 26.69 million shares or 0.78% less from 26.90 million shares in 2017Q4 were reported. Neuberger Berman Group Incorporated invested in 779,865 shares. Voya Investment Ltd Limited Liability Company stated it has 15,123 shares or 0% of all its holdings. American Intll Incorporated owns 20,524 shares or 0% of their US portfolio. Blackrock holds 0% or 2.62 million shares. State Street Corp invested in 690,549 shares. Morgan Stanley has invested 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). Barclays Public Ltd Liability Corporation, United Kingdom-based fund reported 21,438 shares. Tudor Inv Et Al has invested 0.02% in AtriCure, Inc. (NASDAQ:ATRC). 169,490 are owned by Schwab Charles Mngmt. Geode Mgmt Ltd Company accumulated 284,040 shares. First Manhattan has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Wellington Mngmt Group Incorporated Llp has 0.02% invested in AtriCure, Inc. (NASDAQ:ATRC). Atlantic Trust Limited Liability Com holds 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC) for 455 shares. Alphamark Advsr Lc holds 120 shares. Highlander Management Ltd Company invested 0.01% in AtriCure, Inc. (NASDAQ:ATRC).
Since February 15, 2018, it had 2 insider purchases, and 4 sales for $377,050 activity. Krell Elizabeth D sold $200,000 worth of AtriCure, Inc. (NASDAQ:ATRC) on Monday, March 12. Drake Scott William had bought 11,000 shares worth $194,040. Another trade for 4,000 shares valued at $68,120 was made by Noznesky Justin J on Thursday, February 15. GROVES REGINA E had bought 1,000 shares worth $17,430 on Thursday, March 1.